Mesoblast (MESO) EBIT (2014 - 2023)
Mesoblast (MESO) posted EBIT of -$17.5 million for Q2 2023, down 488.27% sequentially from -$3.0 million in Q1 2023, and down 17964.29% YoY from N/an in Q2 2022.
Mesoblast (MESO) EBIT (2014 - 2023) Analysis & Trends
Mesoblast has reported EBIT for 10 years, with the latest figure at -$17.5 million in Q2 2023.
- Quarterly EBIT fell 17964.29% year-over-year to -$17.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$46.7 million (up 19.78% YoY) and the FY2025 annual result came in at -$62.0 million, down 5.53% from the prior year.
- EBIT fell to -$17.5 million in Q2 2023 per MESO's latest filing, from -$3.0 million in the prior quarter.
- Over five years, EBIT peaked at $98000.0 in Q2 2022 and troughed at -$31.4 million in Q4 2021.
- A 5-year average of -$16.5 million and a median of -$17.8 million in 2021 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT jumped 100.54% in 2022, then plunged 17964.29% in 2023.
- Over 5 years, EBIT stood at -$23.3 million in 2019, then rose by 7.0% to -$21.6 million in 2020, then plunged by 45.23% to -$31.4 million in 2021, then soared by 55.83% to -$13.9 million in 2022, then retreated by 26.2% to -$17.5 million in 2023.
- According to Business Quant data, EBIT over the past three periods registered -$17.5 million, -$3.0 million, and -$13.9 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -17.51 Mn |
| Mar 31, 2023 | -2.98 Mn |
| Dec 31, 2022 | -13.87 Mn |
| Sep 30, 2022 | -12.39 Mn |
| Jun 30, 2022 | 98,000.00 |
| Mar 31, 2022 | -8.40 Mn |
| Dec 31, 2021 | -31.41 Mn |
| Sep 30, 2021 | -18.57 Mn |
| Jun 30, 2021 | -18.06 Mn |
| Mar 31, 2021 | -22.66 Mn |
| Dec 31, 2020 | -21.62 Mn |
| Sep 30, 2020 | -21.35 Mn |
| Jun 30, 2020 | -16.99 Mn |
| Mar 31, 2020 | -13.49 Mn |
| Dec 31, 2019 | -23.25 Mn |
| Sep 30, 2019 | -3.84 Mn |
| Jun 30, 2019 | -27.33 Mn |
| Mar 31, 2019 | -24.03 Mn |
| Dec 31, 2018 | -29.96 Mn |
| Sep 30, 2018 | -22.86 Mn |